Caplyta access in Egypt: the EDA named-patient pathway
How patients in the Arab Republic of Egypt legally obtain Caplyta (lumateperone) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.
Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.
Quick orientation
Patients in Egypt access Caplyta (lumateperone) for the treatment of schizophrenia in adults and the treatment of depressive episodes associated with bipolar I or bipolar II disorder in adults, as monotherapy or as adjunctive therapy with lithium or valproate through the EDA named-patient pathway, an Egyptian Drug Authority-administered mechanism that allows an Egyptian-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in EGP.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Reserved for you.
How Caplyta reaches patients in Egypt
Caplyta (lumateperone, an oral atypical antipsychotic with a distinctive serotonin 5-HT2A antagonism plus presynaptic D2 partial agonism and postsynaptic D2 antagonism plus glutamatergic modulation from Intra-Cellular Therapies, now a Johnson and Johnson company following the 2025 acquisition) received US FDA approval in December 2019 for schizophrenia in adults, with a December 2021 indication extension for depressive episodes associated with bipolar I or bipolar II disorder in adults as monotherapy or adjunctive to lithium or valproate, at the 42 mg once-daily oral dose per the FDA label at accessdata.fda.gov/scripts/cder/daf. The FDA label carries the antipsychotic-class boxed warning for increased mortality in elderly patients with dementia-related psychosis and the antidepressant-class warning for suicidal thoughts and behaviours. The Egyptian Drug Authority registered-drug database at eservices.edaegypt.gov.eg shows no public registration record for lumateperone or Caplyta as of 2026-06-01. Egyptian patients access the drug through the Personal Importation of Unregistered Medicines pathway operated by the EDA Central Administration for Pharmaceutical Affairs under Pharmacy Practice Law No. 127 of 1955, Health Minister Decree No. 296 of 2009, and the post-2019 EDA framework at edaegypt.gov.eg. The treating Egyptian-licensed psychiatrist issues a stamped medical report documenting the schizophrenia or bipolar depression diagnosis per DSM-5 or ICD-11 criteria, the prior antipsychotic exposure with response and tolerability history (typical antipsychotics, atypical antipsychotics including risperidone, olanzapine, quetiapine, aripiprazole, brexpiprazole), the metabolic-side-effect rationale where lumateperone's relatively weight-neutral and metabolically lower-risk profile is the prescribing anchor, and the planned 42 mg once-daily oral regimen. EDA does not publish a fixed processing-time SLA; reporting indicates one to three weeks when documentation is complete. Each shipment requires a fresh permit with convention up to a three-month supply.
Where Caplyta is dispensed in Egypt
Caplyta is an oral psychiatric drug administered at home with outpatient psychiatry review of response on PANSS, MADRS, or YMRS scales as appropriate, metabolic monitoring (weight, fasting glucose, lipid panel), and suicidality and movement-disorder surveillance. The Egyptian tertiary psychiatry centres routinely involved in dispensing specialty psychiatric medications and named-patient imports include Ain Shams University Institute of Psychiatry in Cairo, the principal academic psychiatric centre at medicine.asu.edu.eg; Cairo University Hospitals (Kasr Al-Ainy) Department of Neuropsychiatry at kasralainy.edu.eg; the General Secretariat of Mental Health Hospital at Abbasia (formerly Abbassia Mental Hospital) in Cairo, the largest MOHP psychiatric tertiary site at mohp.gov.eg; the Institute of Psychiatry at Alexandria University (Maamoura Mental Hospital) at alexmed.edu.eg; and Mansoura University Hospitals Psychiatry Unit at mans.edu.eg. Among private tertiary psychiatry, Behman Hospital in Helwan at behman.com and Al-Mashfa Hospital at elmashfa.com are recognised inpatient and outpatient providers handling named-patient psychiatric imports. Ain Shams Institute of Psychiatry and Behman Hospital are the most frequent dispensing nodes for novel-mechanism antipsychotics.
What Caplyta costs in Egypt
The US wholesale acquisition cost for Caplyta is reported in manufacturer disclosures tracked through Drugs@FDA at accessdata.fda.gov/scripts/cder/daf at approximately USD 1,450 to USD 1,675 per 30-capsule supply at the labelled 42 mg once-daily dose, with annual drug-only spend in the range of USD 17,000 to USD 20,000. Price snapshot: 2026-06-01. No public local-currency price for Caplyta in Egyptian Pounds is observed in the EDA pricing committee output or the Unified Procurement Authority disclosures at upa.gov.eg as of 2026-06-01; do not estimate. The Central Bank of Egypt USD reference rate has been volatile through 2024 to 2026; families wiring in USD avoid intra-process FX exposure. Cost layers beyond the drug itself include ambient logistics (Caplyta is a room-temperature oral capsule and does not require cold chain), the nominal EDA permit and customs duties, dispensing fees, and the Reserve Meds concierge fee itemised separately on every firm quote.
Funding and access barriers for Caplyta in Egypt
Mental health funding in Egypt is administered through the General Secretariat of Mental Health under MOHP, the largest mental-health-service-delivery body in the Arab world per WHO regional reporting, with treatment at public mental-health hospitals provided largely free for Egyptian nationals. The Universal Health Insurance Authority (UHIA) at uhia.gov.eg includes psychiatric services in its benefit package for insured citizens in implementation governorates; the antipsychotic formulary curated jointly with the Unified Procurement Authority emphasises generic risperidone, olanzapine, quetiapine, and aripiprazole as standard, with newer agents like lumateperone assessed case by case if at all. The Treatment at State Expense scheme (Nafaqat Ala Al-Dawla) administered through MOHP funds case-by-case high-cost treatment for nationals lacking means and has been used for treatment-resistant psychiatric cases. Major private insurers (MetLife Egypt, AXA Egypt, Allianz Egypt, Misr Insurance, GlobeMed Egypt as TPA, Med Net) cover psychiatric care on most retail and group policies with prior authorisation; coverage of unregistered lumateperone specifically is case by case. Mental-health stigma and the structural underfunding of psychiatric services per WHO reporting at who.int shape the access landscape; for patients seeking lumateperone the dominant route is self-pay supplemented where possible by private payer prior authorisation citing inadequate response or intolerance to first-line atypicals. The Egyptian Psychiatric Association and family-support networks are the practical referral routes.
Recent regulatory and access news for Caplyta
Johnson and Johnson completed the acquisition of Intra-Cellular Therapies in April 2025 per public investor disclosure, bringing Caplyta under the Janssen Neuroscience portfolio; the change of corporate sponsor may inform future EDA registration discussions through Johnson and Johnson's Egyptian commercial arm. The European Medicines Agency has not authorised lumateperone in the EU as of 2026-06-01 per the EMA medicines portal at ema.europa.eu/en/medicines, which constrains the reference-authority options Egyptian psychiatrists can cite to the FDA listing and Health Canada (NOC dated 2024) per health-products.canada.ca/dpd-bdpp. The FDA accepted a supplemental new drug application for lumateperone in adjunctive major depressive disorder in 2025 with a PDUFA action date in 2026 per Intra-Cellular Therapies and Johnson and Johnson public disclosures, which would further widen the in-label patient population if approved. UHIA and the Unified Procurement Authority have continued the phased UHI rollout across governorates per UHIA bulletins at uhia.gov.eg. No drug-specific EDA bulletin for Caplyta or lumateperone over the last 12 months has been observed as of 2026-06-01.
Where Reserve Meds fits in Caplyta cases
Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace EDA, and we do not replace your dispensing pharmacy. For Caplyta specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Egypt, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.
Operationally, a typical Caplyta case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the EDA application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.
Caplyta is administered orally once daily at 42 mg; psychiatry follow-up monitors response, metabolic and weight parameters, somnolence, and the labelled boxed warning regarding increased mortality in elderly patients with dementia-related psychosis.
Next step
If your Egyptian physician has prescribed Caplyta and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.
Reserved for you.